These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 18406882)

  • 1. A novel MRI marker for prostate brachytherapy.
    Frank SJ; Stafford RJ; Bankson JA; Li C; Swanson DA; Kudchadker RJ; Martirosyan KS
    Int J Radiat Oncol Biol Phys; 2008 May; 71(1):5-8. PubMed ID: 18406882
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anisotropy characterization of I-125 seed with attached encapsulated cobalt chloride complex contrast agent markers for MRI-based prostate brachytherapy.
    Frank SJ; Tailor RC; Kudchadker RJ; Martirosyan KS; Stafford RJ; Elliott AM; Swanson DA; Sing D; Choi J; Mourtada F; Ibbott GS
    Med Dosim; 2011; 36(2):200-5. PubMed ID: 20537886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Magnetic resonance imaging (MRI) markers for MRI-guided high-dose-rate brachytherapy: novel marker-flange for cervical cancer and marker catheters for prostate cancer.
    Schindel J; Muruganandham M; Pigge FC; Anderson J; Kim Y
    Int J Radiat Oncol Biol Phys; 2013 Jun; 86(2):387-93. PubMed ID: 23433797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Accuracy of seed reconstruction in prostate postplanning studied with a CT- and MRI-compatible phantom.
    De Brabandere M; Kirisits C; Peeters R; Haustermans K; Van den Heuvel F
    Radiother Oncol; 2006 May; 79(2):190-7. PubMed ID: 16707176
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive I-125 multi-seed comparison for prostate brachytherapy: dosimetry and visibility analysis.
    Al-Qaisieh B; Smith DW; Brearley E; St Clair S; Bownes P
    Radiother Oncol; 2007 Aug; 84(2):140-7. PubMed ID: 17588696
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Update of prostate magnetic resonance imaging at 3 T.
    Kim CK; Park BK
    J Comput Assist Tomogr; 2008; 32(2):163-72. PubMed ID: 18379296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MRI/TRUS data fusion for brachytherapy.
    Daanen V; Gastaldo J; Giraud JY; Fourneret P; Descotes JL; Bolla M; Collomb D; Troccaz J
    Int J Med Robot; 2006 Sep; 2(3):256-61. PubMed ID: 17520640
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Applicator reconstruction in MRI 3D image-based dose planning of brachytherapy for cervical cancer.
    Haack S; Nielsen SK; Lindegaard JC; Gelineck J; Tanderup K
    Radiother Oncol; 2009 May; 91(2):187-93. PubMed ID: 18977049
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MRI-guided prostate brachytherapy with single needle method--a planning study.
    Van Gellekom MP; Moerland MA; Battermann JJ; Lagendijk JJ
    Radiother Oncol; 2004 Jun; 71(3):327-32. PubMed ID: 15172149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of pulse sequence parameter selection on signal strength in positive-contrast MRI markers for MRI-based prostate postimplant assessment.
    Lim TY; Kudchadker RJ; Wang J; Stafford RJ; MacLellan C; Rao A; Ibbott GS; Frank SJ
    Med Phys; 2016 Jul; 43(7):4312. PubMed ID: 27370146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pushing the sensitivity envelope of lanthanide-based magnetic resonance imaging (MRI) contrast agents for molecular imaging applications.
    Aime S; Castelli DD; Crich SG; Gianolio E; Terreno E
    Acc Chem Res; 2009 Jul; 42(7):822-31. PubMed ID: 19534516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparative study of seed localization and dose calculation on pre- and post-implantation ultrasound and CT images for low-dose-rate prostate brachytherapy.
    Ali I; Algan O; Thompson S; Sindhwani P; Herman T; Cheng CY; Ahmad S
    Phys Med Biol; 2009 Sep; 54(18):5595-611. PubMed ID: 19717887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MRI characterization of cobalt dichloride-N-acetyl cysteine (C4) contrast agent marker for prostate brachytherapy.
    Lim TY; Stafford RJ; Kudchadker RJ; Sankaranarayanapillai M; Ibbott G; Rao A; Martirosyan KS; Frank SJ
    Phys Med Biol; 2014 May; 59(10):2505-16. PubMed ID: 24778352
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sequential comparison of seed loss and prostate dosimetry of stranded seeds with loose seeds in 125I permanent implant for low-risk prostate cancer.
    Saibishkumar EP; Borg J; Yeung I; Cummins-Holder C; Landon A; Crook J
    Int J Radiat Oncol Biol Phys; 2009 Jan; 73(1):61-8. PubMed ID: 18823713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate postbrachytherapy seed distribution: comparison of high-resolution, contrast-enhanced, T1- and T2-weighted endorectal magnetic resonance imaging versus computed tomography: initial experience.
    Bloch BN; Lenkinski RE; Helbich TH; Ngo L; Oismueller R; Jaromi S; Kubin K; Hawliczek R; Kaplan ID; Rofsky NM
    Int J Radiat Oncol Biol Phys; 2007 Sep; 69(1):70-8. PubMed ID: 17513062
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Usefulness of diffusion-weighted imaging and dynamic contrast-enhanced magnetic resonance imaging in the diagnosis of prostate transition-zone cancer.
    Yoshizako T; Wada A; Hayashi T; Uchida K; Sumura M; Uchida N; Kitagaki H; Igawa M
    Acta Radiol; 2008 Dec; 49(10):1207-13. PubMed ID: 19031184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MRI of prostate brachytherapy seeds at high field: a study in phantom.
    Thomas SD; Wachowicz K; Fallone BG
    Med Phys; 2009 Nov; 36(11):5228-34. PubMed ID: 19994533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contrast agents: magnetic resonance.
    Burtea C; Laurent S; Vander Elst L; Muller RN
    Handb Exp Pharmacol; 2008; (185 Pt 1):135-65. PubMed ID: 18626802
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inverse planning simulated annealing for magnetic resonance imaging-based intracavitary high-dose-rate brachytherapy for cervical cancer.
    Kubicky CD; Yeh BM; Lessard E; Joe BN; Speight JL; Pouliot J; Hsu IC
    Brachytherapy; 2008; 7(3):242-7. PubMed ID: 18468959
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Magnetic resonance imaging assessment of a convective therapy delivery paradigm in a canine prostate model.
    Shetty AM; Stafford RJ; Elliott AM; Kassouf W; Brown GA; Stephens LC; Tinkey PT; Bidaut L; Pisters LL; Hazle JD
    J Magn Reson Imaging; 2007 Dec; 26(6):1672-7. PubMed ID: 17968888
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.